Utpal Koppikar
Director/Board Member at C4 THERAPEUTICS, INC.
Net worth: 172 592 $ as of 31/03/2024
Profile
Utpal Koppikar is an Independent Director at C4 Therapeutics, Inc. He previously worked as a Director at Flexion Therapeutics, Inc. and as Vice President-Corporate & Operations Finance at Gilead Sciences, Inc. He is also the Chief Financial Officer & Senior Vice President at Atara Biotherapeutics, Inc. Mr. Koppikar holds a graduate degree from Stanford University, an undergraduate degree from the University of Maryland, and an MBA from UCLA Anderson School of Management.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 02/03/2023 | 181,978 ( 0.14% ) | 126 293 $ | 31/03/2024 | |
C4 THERAPEUTICS, INC.
0.01% | 15/06/2023 | 5,667 ( 0.01% ) | 46 299 $ | 31/03/2024 |
Utpal Koppikar active positions
| Companies | Position | Start |
|---|---|---|
| C4 THERAPEUTICS, INC. | Director/Board Member | 16/03/2022 |
Former positions of Utpal Koppikar
| Companies | Position | End |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Director of Finance/CFO | 31/03/2023 |
| FLEXION THERAPEUTICS, INC. | Director/Board Member | 19/11/2021 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/06/2018 |
Training of Utpal Koppikar
| Stanford University | Graduate Degree |
| University of Maryland | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| C4 THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
- Stock Market
- Insiders
- Utpal Koppikar
